[The progression of liver fibrosis in prison inmates co-infected by HIV and HCV who started on boosted protease inhibitor therapy]. / Evolución de la fibrosis hepática en reclusos coinfectados por VIH y VHC que inician tratamiento con inhibidores de la proteasa potenciados.

OBJECTIVES: To analyse the progression of liver fibrosis as measured by elastography and biochemical testing in prisoninmates co-infected by HIV and HCVwho started on ritonavir-boosted protease inhibitor (PI) therapy. METHODS: A prospective, observational and multi-centre study. The progression of liver fibrosis as measured by transient elastography (FibroScan) and biochemical testing was monitored for 48 weeks in a Spanish prison population co-infected with HIV and HCV. RESULTS: Of the 94 patients included, 54 (57.4%) were followed-up for 48 weeks. At week 48, no significant changes were seen in the grade of fibrosis measured using FibroScan (8.1 kPa vs. 8.3 kPa; p=0.20) or the Forns index (5.6 vs. 5.1; p= 0.50), although significant changes were detected using the APRI (0.7 vs. 0.6; p=0.05) and the FIB-4 indexes (p= 0.02).When measurement was done compared to baseline fibrosis, it was seen that therapy reduced the percentage of patients with fibrosis ≥3 but <4 (50% vs. 15%; p=0.001), but no change was seen in those found to have grade 4 fibrosis at baseline (20.4% vs. 20.4%). CONCLUSION: The inmates co-infected with HIV and HCV who were started on antiretroviral therapy with the boosted protease inhibitor (PI) showed stasterilizationbilisation of the liver fibrosis as measured with FibroScan after one year of follow-up. Overall, the therapy improved fibrosis when measured using the APRI or FIB-4 indexes, but not when using the Forns index or elastography.

Evolución de la fibrosis hepática en reclusos coinfectados por VIH y VHC que inician tratamiento con inhibidores de la proteasa potenciados / The progression of liver fibrosis in prison inmates co-infected by HIV and HCV who started on boosted protease inhibitor therapy

Objetivos: Analizar la evolución de la fibrosis hepática medida por elastografía y pruebas bioquímicas en reclusos coinfectados por VIH y VHC que han iniciado tratamiento antirretroviral con lopinavir/ritonavir u otros inhibidores de la proteasa potenciados con ritonavir. Métodos: Estudio prospectivo, observacional y multicéntrico. Se comprobó durante 48 semanas la evolución de la fibrosis hepática medida mediante elastografía de transición (FibroScan) y pruebas bioquímicas en población penitenciaria española coinfectada por VIH y VHC. Resultados: De los 94 pacientes incluidos, 54 (57,4%) fueron seguidos durante 48 semanas. En la semana 48, no hubo cambios significativos en el grado de fibrosis medida mediante FibroScan (8,1 Kpa vs 8,3; p=0.20) o índice de FORNS (5,6 vs 5,1; p=0,50), aunque sí con el índice APRI (0.7 vs 0.6; p=0.05) y el índice FIB-4 (p=0,02). Cuando la medición se realizó en función del grado de fibrosis basal, se observó que el tratamiento redujo el porcentaje de pacientes con fibrosis basal de grado 3/4 (50% vs 15%; p=0,001), pero no hubo cambios en los que ya tenían basalmente grado 4 (20,4% vs 20,4%). Conclusión: Los reclusos coinfectados por VIH y VHC que inician tratamiento antirretroviral con lopinavir/ritonavir muestran una estabilización de la fibrosis hepática medida con FibroScan® tras un año de seguimiento. En conjunto, el tratamiento mejoró la fibrosis cuando la referencia de medición fue el índice APRI y el FIB-4, pero no con el índice FORNS o la elastografía (AU)

Objectives: To analyse the progression of liver fibrosis as measured by elastography and biochemical testing in prison inmates co-infected by HIV and HCVwho started on ritonavir-boosted protease inhibitor (PI) therapy. Methods: A prospective, observational and multi-centre study. The progression of liver fibrosis as measured by transient elastography (FibroScan) and biochemical testing was monitored for 48 weeks in a Spanish prison population co-infected with HIV and HCV. Results: Of the 94 patients included, 54 (57.4%) were followed-up for 48 weeks. At week 48, no significant changes were seen in the grade of fibrosis measured using FibroScan (8.1 kPa vs. 8.3 kPa; p=0.20) or the Forns index (5.6 vs. 5.1; p=0.50), although significant changes were detected using the APRI (0.7 vs. 0.6; p=0.05) and the FIB-4 indexes (p= 0.02).When measurement was done compared to baseline fibrosis, it was seen that therapy reduced the percentage of patients with fibrosis ≥3 but <4 (50% vs. 15%; p=0.001), but no change was seen in those found to have grade 4 fibrosis at baseline (20.4% vs. 20.4%). Conclusion: The inmates co-infected with HIV and HCV who were started on antiretroviral therapy with the boosted protease inhibitor (PI) showed stasterilizationbilisation of the liver fibrosis as measured with FibroScan after one year of follow-up. Overall, the therapy improved fibrosis when measured using the APRI or FIB-4 indexes, but not when using the Forns index or elastography (AU)

[Description of the psychiatric unit in prisons in the autonomous community of Valencia]. / Descripción de la consulta psiquiátrica en centros penitenciarios de la Comunidad Valenciana.

INTRODUCTION: Little work has been done on the contents of psychiatric consultancies in prisons. AIMS: To explore the sociodemographic, clinical and treatment profile of the patients who were assessed in the psychiatric consultancy of three prisons. METHODS: This is a prospective, longitudinal, descriptive and multicenter-based epidemiological study of patients who were assessed in the psychiatric consultacy of three prisons in the Autonomous Community of Valencia from 2009 to 2011. Sociodemographic, clinical and prison data was obtained from each patient. Their frequency was compared with Pearson's Ji² and averages with the ANOVA test or with The Kruskall-Wallis method. The probability of keeping the patients in schedule was calculated with Kaplan-Meier's curves and differences with the Mantel-Haenzsel method (Logrank) were established. A logistic regression model was designed to determine the data linked to frequent users. RESULTS: 786 patients were assessed in 2,006 visits (2.5 visits/patient). 90% were male, 88.2% Spanish and their average age was 36 years. 29.9% suffered from an infectious chronic pathology. 69.5% used some kinds of substance. 59.2% suffered from personality disorder and 11.6% from the spectrum of schizophrenia. The most frequent medical profiles were: 49.1% with anxiety disorder, 20.8% depressive disorder and 11.7% psychotic disorder. These psychotic disorders meant a greater probability of 1.5 times for maintaining in schedule. The most commonly prescribed medications were quetiapine, mirtazapine, pregabalin and diazepam. CONCLUSION: There is a high prevalence of mental disorders in prisons. It is necessary to improve the available resources to deal with these pathologies in the most effective way.

Descripción de la consulta psiquiátrica en centros penitenciarios de la Comunidad Valenciana / Description of the psychiatric unit in prisons in the Autonomous Community of Valencia

Introducción: Existen pocos trabajos sobre el contenido de las consultas psiquiátricas en las prisiones. Objetivos: Explorar el perfil sociodemográfico, clínico y de tratamiento de los pacientes valorados en la consulta psiquiátrica de tres centros penitenciarios. Métodos: Estudio epidemiológico multicéntrico, descriptivo, longitudinal, y prospectivo de los pacientes valorados en la consulta psiquiátrica de tres prisiones de la Comunidad Valenciana durante 2009, 2010 y 2011. Se obtuvieron variables clínicas, sociodemográficas y penitenciarias de cada paciente. Las frecuencias se compararon mediante la Ji2 de Pearson y las medias por el test de ANOVA o el método de Kruskall-Wallis. Se calculó la probabilidad de mantenerse en agenda psiquiátrica mediante curvas de Kaplan-Meier, estableciéndose las diferencias con el método de Mantel- Haenzsel (Logrank). Se diseñó un modelo de regresión logística para determinar las variables asociadas a hiperfrecuentación. Resultados: Se valoraron 786 pacientes en 2.006 consultas (2,5 visitas/paciente). El 90% eran varones y el 88,2% españoles, con una edad media de 36,0 años. El 29,9% tenían patología infecciosa crónica asociada. El 69,5% consume algún tipo de sustancia. El 59,2% sufría un trastorno de personalidad y el 11,6% del espectro de la esquizofrenia. Los cuadros clínicos más frecuentes fueron; 49,1% cuadros ansiosos, 20,8% depresivos y 11,7% síntomas psicóticos. Los trastornos psicóticos supusieron 1,5 veces más probabilidad (IC 95%; 1,1-1,9) de mantenerse más tiempo en agenda. Los fármacos más prescritos fueron quetiapina, mirtazapina, pregabalina y diacepam. Conclusiones: Los trastornos mentales en prisión son muy prevalentes. Es necesario potenciar los recursos disponibles para una adecuada atención de estas patologías(AU)

Introduction: Little work has been done on the contents of psychiatric consultancies in prisons. Aims: To explore the sociodemographic, clinical and treatment profile of the patients who were assessed in the psychiatric consultancy of three prisons. Methods: This is a prospective, longitudinal, descriptive and multicenter-based epidemiological study of patients who were assessed in the psychiatric consultacy of three prisons in the Autonomous Community of Valencia from 2009 to 2011. Sociodemographic, clinical and prison data was obtained from each patient. Their frequency was compared with Pearson’s Ji2 and averages with the ANOVA test or with The Kruskall-Wallis method. The probability of keeping the patients in schedule was calculated with Kaplan-Meier’s curves and differences with the Mantel-Haenzsel method (Logrank) were established. A logistic regression model was designed to determine the data linked to frequent users. Results: 786 patients were assessed in 2,006 visits (2.5 visits/patient). 90% were male, 88.2% Spanish and their average age was 36 years. 29.9% suffered from an infectious chronic pathology. 69.5% used some kinds of substance. 59.2% suffered from personality disorder and 11.6% from the spectrum of schizophrenia. The most frequent medical profiles were: 49.1% with anxiety disorder, 20.8% depressive disorder and 11.7% psychotic disorder. These psychotic disorders meant a greater probability of 1.5 times for maintaining in schedule. The most commonly prescribed medications were quetiapine, mirtazapine, pregabalin and diazepam. Conclusion: There is a high prevalence of mental disorders in prisons. It is necessary to improve the available resources to deal with these pathologies in the most effective way(AU)

Mutaciones asociadas a resistencia a fármacos antirretrovirales en una población penitenciaria "Naïve" / Mutations associated with resistance to antiretroviral medication in a previously untreated prison population

Objetivo: Determinar la existencia de mutaciones asociadas a resistencias a fármacos antirretrovirales en una población penitenciaria infectada por el VIH y sin tratamiento antirretroviral previo. Material y Método: Estudio descriptivo, transversal en el que se examinan genotipos del VIH procedentes de muestras plasmáticas de los pacientes VIH+ naives del C.P. de Castellón. Las muestras se analizan en el Instituto Valenciano de Microbiología de Bétera (Valencia) mediante doble amplificación por PCR y posterior secuenciación con secuenciador automático de Perkin-Elmer; secuencia de referencia: la cepa salvaje HXB2 del VIH. La proporción de mutantes existentes se expresan en porcentajes sobre el total de la muestra y el resto de los datos se procesan con el paquete estadístico Epiinfo 6.0. Resultados: De 25 muestras, en una no había material genético suficiente para amplificar. En las 24 restantes no se encuentran mutaciones de resistencia a INTI. 7 pacientes (32 por ciento), presentan mutaciones de resistencia a IP: 4 presentan la L63P, 2 la V77I y un paciente una mutación doble: L63P+V77I. Conclusiones: Nuestros resultados sugieren que en nuestro medio seguimos pudiendo instaurar tratamientos antirretrovirales en infectados naïves de forma empírica; no obstante la cortedad de la muestra y su focalización geográfica obligan a seguir realizando estudios de este tipo para confirmarlo (AU)